The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
Open accessAbstract
Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung carcinoma patients, progression during treatment eventually develops. Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation. In addition, some patients progress due to cancer metastasis in the brain. Using structure-based drug design, lipophilic efficiency, and physical-property-based optimization, highly potent macrocyclic ALK inhibitors were prepared with good absorption, distribution, metabolism, and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability. These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clinically reported ALK kinase domain mutations. Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms. This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Kaminski, G. A., Friesner, R. A., Tirado-Rives, J., & Jorgensen, W. L. (2001) · The Journal of Physical Chemistry B · doi:10.1021/jp003919d · Cited by 4,060
Mohamadi, F., Richards, N. G. J., Guida, W. C., Liskamp, R., Lipton, M., Caufield, C., Chang, G., Hendrickson, T., & Still, W. C. (1990) · Journal of Computational Chemistry · doi:10.1002/jcc.540110405 · Cited by 3,757
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,409
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Recent advances in Sonogashira reactions
Chinchilla, R., & Nájera, C. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15071e · Cited by 1,541
Palladium‐Catalyzed Carbonylation Reactions of Aryl Halides and Related Compounds
Brennführer, A., Neumann, H., & Beller, M. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200900013 · Cited by 1,463
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407
The exploration of macrocycles for drug discovery — an underexploited structural class
Driggers, E. M., Hale, S. P., Lee, J., & Terrett, N. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2590 · Cited by 1,370
Allylic 1,3-strain as a controlling factor in stereoselective transformations
Hoffmann, R. W. (1989) · Chemical Reviews · doi:10.1021/cr00098a009 · Cited by 1,257
Mitsunobu and Related Reactions: Advances and Applications
Swamy, K. C. K., Kumar, N. N. B., Balaraman, E., & Kumar, K. V. P. P. (2009) · Chemical Reviews · doi:10.1021/cr800278z · Cited by 1,184
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Ring closure reactions of bifunctional chain molecules
Illuminati, G., & Mandolini, L. (1981) · Accounts of Chemical Research · doi:10.1021/ar00064a001 · Cited by 991
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
Gleeson, M. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701122q · Cited by 969
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
Self-citationOncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 916
Shaw, A. T., Yeap, B. Y., Solomon, B. J., Riely, G. J., Gainor, J., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S.-H. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 899
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 894
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
Marsault, E., & Peterson, M. L. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1012374 · Cited by 843
The Challenge of Atropisomerism in Drug Discovery
Clayden, J., Moran, W. J., Edwards, P. J., & LaPlante, S. R. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200901719 · Cited by 783
Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R., Yamazaki, S., Koudriakova, T. B., Alton, G., Cui, J. J., Kung, P.-P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4443 · Cited by 745
Self-citationChristensen, J. G., Zou, H. Y., Arango, M. E., Li, Q., Lee, J. H., McDonnell, S. R., Yamazaki, S., Alton, G. R., Mroczkowski, B., & Los, G. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0365 · Cited by 649
Self-citationCH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Sakamoto, H., Tsukaguchi, T., Hiroshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., Oikawa, N., Tsukuda, T., Ishii, N., & Aoki, Y. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.004 · Cited by 636
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Costa, D. B., Kobayashi, S., Pandya, S. S., Yeo, W.-L., Shen, Z., Tan, W., & Wilner, K. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1313 · Cited by 596
Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.
Griffin, C. A., Hawkins, A. L., Dvorak, C. C., Henkle, C., Ellingham, T. J., & Perlman, E. J. (1999) · PubMed · Cited by 571
Intramolecular Hydrogen Bonding in Medicinal Chemistry
Kuhn, B., Mohr, P., & Stahl, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100087s · Cited by 571
Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
Giordanetto, F., & Kihlberg, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400887j · Cited by 563
Katayama, R., Khan, T. M., Benes, C., Lifshits, E., Ebi, H., Rivera, V. M., Shakespeare, W. C., Iafrate, A. J., Engelman, J. A., & Shaw, A. T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019559108 · Cited by 542
Revealing Atropisomer Axial Chirality in Drug Discovery
LaPlante, S. R., Edwards, P. J., Fader, L. D., Jakalian, A., & Hucke, O. (2011) · ChemMedChem · doi:10.1002/cmdc.201000485 · Cited by 535
Morris, S. W., Naeve, C., Mathew, P., James, P. L., Kirstein, M. N., Cui, X., & Witte, D. P. (1997) · Oncogene · doi:10.1038/sj.onc.1201062 · Cited by 524
Feng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., & de Morais, S. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017434 · Cited by 440
Marsilje, T. H., Pei, W., Chen, B., Lu, W., Uno, T., Jin, Y., Jiang, T., Kim, S., Li, N., Warmuth, M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400402q · Cited by 418
Redzic, Z. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-3 · Cited by 418
Using the Golden Triangle to optimize clearance and oral absorption
Johnson, T. W., Dress, K. R., & Edwards, M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.045 · Cited by 392
Self-citationIdentification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Galkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609412103 · Cited by 379
Brain metastases as preventive and therapeutic targets
Steeg, P. S., Camphausen, K. A., & Smith, Q. R. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3053 · Cited by 363
Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
Gainor, J. F., & Shaw, A. T. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0095 · Cited by 342
Targeting Anaplastic Lymphoma Kinase in Lung Cancer
Shaw, A. T., & Solomon, B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1591 · Cited by 308
Carén, H., Abel, F., Kogner, P., & Martinsson, T. (2008) · Biochemical Journal · doi:10.1042/bj20081834 · Cited by 280
Ryckmans, T., Edwards, M. P., Horne, V. A., Correia, A. M., Owen, D. R., Thompson, L. R., Tran, I., Tutt, M. F., & Young, T. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.062 · Cited by 270
Self-citationNon‐solid oncogenes in solid tumors: EML4–ALK fusion genes in lung cancer
Mano, H. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00972.x · Cited by 229
What can a chemist learn from nature?s macrocycles? ? A brief, conceptual view
Wessjohann, L. A., Ruijter, E., Garcia-Rivera, D., & Brandt, W. (2005) · Molecular Diversity · doi:10.1007/s11030-005-1314-x · Cited by 222
Conformation‐Directed Macrocyclization Reactions
Blankenstein, J., & Zhu, J. (2005) · European Journal of Organic Chemistry · doi:10.1002/ejoc.200400751 · Cited by 202
Self-citationBilsland, J. G., Wheeldon, A., Mead, A., Znamenskiy, P., Almond, S., Waters, K. A., Thakur, M., Beaumont, V., Bonnert, T. P., Heavens, R., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301446 · Cited by 188
Beau, M. M. L., Bitter, M., Larson, R. A., et al. (1989) · PubMed · Cited by 180
Species Independence in Brain Tissue Binding Using Brain Homogenates
Di, L., Umland, J. P., Chang, G., Huang, Y., Lin, Z., Scott, D. O., Troutman, M. D., & Liston, T. E. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038778 · Cited by 160
Han, G., Tamaki, M., & Hruby, V. J. (2001) · The Journal of Peptide Research · doi:10.1034/j.1399-3011.2001.00935.x · Cited by 156
Lipophilic Efficiency: The Most Important Efficiency Metric in Medicinal Chemistry
Freeman‐Cook, K. D., Hoffman, R. L., & Johnson, T. W. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.208 · Cited by 139
Self-citationKodaira, H., Kusuhara, H., Fujita, T., Ushiki, J., Fuse, E., & Sugiyama, Y. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180398 · Cited by 132
Huang, Q., Johnson, T. W., Bailey, S., Brooun, A., Bunker, K. D., Burke, B. J., Collins, M. R., Cook, A. S., Cui, J. J., Dack, K. N., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401805h · Cited by 124
Self-citationEmerging importance of ALK in neuroblastoma
Azarova, A. M., Gautam, G., & George, R. E. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.09.005 · Cited by 124
The Crystal Structures of TrkA and TrkB Suggest Key Regions for Achieving Selective Inhibition
Bertrand, T., Kothe, M., Liu, J., Dupuy, A., Rak, A., Berne, P., Davis, S. H., Gladysheva, T. B., Valtre, C., Crenne, J. Y., et al. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.08.002 · Cited by 124
Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer
Ren, H., Tan, Z., Zhu, X., Crosby, K., Haack, H., Ren, J., Beausoleil, S. A., Moritz, A., Innocenti, G., Rush, A. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3931 · Cited by 124
Kinoshita, K., Kobayashi, T., Asoh, K., Furuichi, N., Ito, T., Kawada, H., Hara, S., Ohwada, J., Hattori, K., Miyagi, T., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200652u · Cited by 89
Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors
Kinoshita, K., Ono, Y., Emura, T., Asoh, K., Furuichi, N., Ito, T., Kawada, H., Tanaka, S., Morikami, K., Tsukaguchi, T., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.020 · Cited by 40
He, H., Lyons, K. A., Shen, X., Yao, Z., Bleasby, K., Chan, G. C., Hafey, M. J., Li, X., Xu, S., Salituro, G., et al. (2009) · Xenobiotica · doi:10.1080/00498250903015402 · Cited by 28
Anaplastic Lymphoma Kinase Inhibitors for the Treatment of ALK-Positive Cancers
Kinoshita, K., Oikawa, N., & Tsukuda, T. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00019-9 · Cited by 27
Synthetic Macrocycles in Small-Molecule Drug Discovery
Vendeville, S., & Cummings, M. D. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00023-5 · Cited by 26
Cui, J. J., McTigue, M. A., Kania, R. S., & Edwards, M. P. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00025-9 · Cited by 23
Self-citation
Cited by
Modern advances in heterocyclic chemistry in drug discovery
Taylor, A. P., Robinson, R. P., Fobian, Y. M., Blakemore, D. C., Jones, L. H., & Fadeyi, O. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00936k · Cited by 887
Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30649-1 · Cited by 791
Shaw, A. T., Felip, E., Bauer, T. M., Besse, B., Navarro, A., Postel-Vinay, S., Gainor, J. F., Johnson, M., Dietrich, J., James, L. P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30680-0 · Cited by 659
CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Targeting ALK: Precision Medicine Takes on Drug Resistance
Lin, J. J., Riely, G. J., & Shaw, A. T. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1123 · Cited by 522
Metadata
- Authors
- Johnson, T. W., Richardson, P. F., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., Cui, J. J., Deal, J. G., Deng, Y.-L., Dinh, D., Engstrom, L. D., He, M., Hoffman, J., Hoffman, R. L., Huang, Q., Kania, R. S., Kath, J. C., Lam, H., Lam, J. L., Le, P. T., Lingardo, L., Liu, W., McTigue, M., Palmer, C. L., Sach, N. W., Smeal, T., Smith, G. L., Stewart, A. E., Timofeevski, S., Zhu, H., Zhu, J., Zou, H. Y., & Edwards, M. P.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-06-03
- Volume
- 57
- Issue
- 11
- Pages
- 4720-4744
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2784414491
- Cited by
- 594
- References
- 62
- FWCI
- 30.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.